These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 35871521)

  • 41. Evaluation of the neurofilament light chain as a biomarker in children with spinal muscular atrophy treated with nusinersen.
    Seo G; Kim S; Byun JC; Kwon S; Lee YJ
    Brain Dev; 2023 Nov; 45(10):554-563. PubMed ID: 37541812
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1.
    Dabbous O; Maru B; Jansen JP; Lorenzi M; Cloutier M; Guérin A; Pivneva I; Wu EQ; Arjunji R; Feltner D; Sproule DM
    Adv Ther; 2019 May; 36(5):1164-1176. PubMed ID: 30879249
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study.
    Hagenacker T; Wurster CD; Günther R; Schreiber-Katz O; Osmanovic A; Petri S; Weiler M; Ziegler A; Kuttler J; Koch JC; Schneider I; Wunderlich G; Schloss N; Lehmann HC; Cordts I; Deschauer M; Lingor P; Kamm C; Stolte B; Pietruck L; Totzeck A; Kizina K; Mönninghoff C; von Velsen O; Ose C; Reichmann H; Forsting M; Pechmann A; Kirschner J; Ludolph AC; Hermann A; Kleinschnitz C
    Lancet Neurol; 2020 Apr; 19(4):317-325. PubMed ID: 32199097
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials.
    Darras BT; Farrar MA; Mercuri E; Finkel RS; Foster R; Hughes SG; Bhan I; Farwell W; Gheuens S
    CNS Drugs; 2019 Sep; 33(9):919-932. PubMed ID: 31420846
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nusinersen treatment of Spinal Muscular Atrophy Type 1 - results of expanded access programme in Poland.
    Modrzejewska S; Kotulska K; Kopyta I; Grędowska E; Emich-Widera E; Tomaszek K; Paprocka J; Chmielewski D; Pilch J; Pietruszewski J; Lemska A; Zawadzka M; Mazurkiewicz-Bełdzińska M
    Neurol Neurochir Pol; 2021; 55(3):289-294. PubMed ID: 33565602
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studies.
    Darras BT; Chiriboga CA; Iannaccone ST; Swoboda KJ; Montes J; Mignon L; Xia S; Bennett CF; Bishop KM; Shefner JM; Green AM; Sun P; Bhan I; Gheuens S; Schneider E; Farwell W; De Vivo DC;
    Neurology; 2019 May; 92(21):e2492-e2506. PubMed ID: 31019106
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study.
    Acsadi G; Crawford TO; Müller-Felber W; Shieh PB; Richardson R; Natarajan N; Castro D; Ramirez-Schrempp D; Gambino G; Sun P; Farwell W
    Muscle Nerve; 2021 May; 63(5):668-677. PubMed ID: 33501671
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety analysis of laboratory parameters in paediatric patients with spinal muscular atrophy treated with nusinersen.
    Zhu X; Li H; Hu C; Wu M; Zhou S; Wang Y; Li W
    BMC Pediatr; 2024 Jul; 24(1):474. PubMed ID: 39054521
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3: The Phase 2 TOPAZ Study.
    Crawford TO; Darras BT; Day JW; Dunaway Young S; Duong T; Nelson LL; Barrett D; Song G; Bilic S; Cote S; Sadanowicz M; Iarrobino R; Xu TJ; O'Neil J; Rossello J; Place A; Kertesz N; Nomikos G; Chyung Y
    Neurology; 2024 Mar; 102(5):e209151. PubMed ID: 38330285
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evolution of bulbar function in spinal muscular atrophy type 1 treated with nusinersen.
    Weststrate H; Stimpson G; Thomas L; Scoto M; Johnson E; Stewart A; Muntoni F; Baranello G; Conway E;
    Dev Med Child Neurol; 2022 Jul; 64(7):907-914. PubMed ID: 35103306
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Clinical follow-up analysis of nusinersen in the disease-modifying treatment of pediatric spinal muscular atrophy].
    Mao SS; Feng YJ; Xu L; Yao M; Xia Y; Jin JN; Wang LS; Chen TT; Chen XY; Zhang Y; Zhang H; Jiang Y; Li HB; Long Q; Gao F
    Zhonghua Er Ke Za Zhi; 2022 Jul; 60(7):688-693. PubMed ID: 35768357
    [No Abstract]   [Full Text] [Related]  

  • 52. Real-World Data from Nusinersen Treatment for Patients with Later-Onset Spinal Muscular Atrophy: A Single Center Experience.
    Mendonça RH; Polido GJ; Matsui C; Silva AMS; Solla DJF; Reed UC; Zanoteli E
    J Neuromuscul Dis; 2021; 8(1):101-108. PubMed ID: 33074187
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany.
    Pechmann A; Langer T; Schorling D; Stein S; Vogt S; Schara U; Kölbel H; Schwartz O; Hahn A; Giese K; Johannsen J; Denecke J; Weiß C; Theophil M; Kirschner J
    J Neuromuscul Dis; 2018; 5(2):135-143. PubMed ID: 29689734
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Respiratory and sleep outcomes in children with SMA treated with nusinersen - real world experience.
    Gonski K; Chuang S; Teng A; Thambipillay G; Farrar MA; Menezes MP; Fitzgerald DA
    Neuromuscul Disord; 2023 Jun; 33(6):531-538. PubMed ID: 37290230
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden.
    Zuluaga-Sanchez S; Teynor M; Knight C; Thompson R; Lundqvist T; Ekelund M; Forsmark A; Vickers AD; Lloyd A
    Pharmacoeconomics; 2019 Jun; 37(6):845-865. PubMed ID: 30714083
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nusinersen treatment and cerebrospinal fluid neurofilaments: An explorative study on Spinal Muscular Atrophy type 3 patients.
    Faravelli I; Meneri M; Saccomanno D; Velardo D; Abati E; Gagliardi D; Parente V; Petrozzi L; Ronchi D; Stocchetti N; Calderini E; D'Angelo G; Chidini G; Prandi E; Ricci G; Siciliano G; Bresolin N; Comi GP; Corti S; Magri F; Govoni A
    J Cell Mol Med; 2020 Mar; 24(5):3034-3039. PubMed ID: 32032473
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nusinersen treatment significantly improves hand grip strength, hand motor function and MRC sum scores in adult patients with spinal muscular atrophy types 3 and 4.
    De Wel B; Goosens V; Sobota A; Van Camp E; Geukens E; Van Kerschaver G; Jagut M; Claes K; Claeys KG
    J Neurol; 2021 Mar; 268(3):923-935. PubMed ID: 32935160
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Respiratory outcome of spinal muscular atrophy type 1 patients treated with nusinersen.
    Ergenekon AP; Yilmaz Yegit C; Cenk M; Gokdemir Y; Erdem Eralp E; Ozturk G; Unver O; Kenis Coskun O; Karadag Saygi E; Turkdogan D; Karadag B
    Pediatr Int; 2022 Jan; 64(1):e15175. PubMed ID: 35522792
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nusinersen for SMA: expanded access programme.
    Farrar MA; Teoh HL; Carey KA; Cairns A; Forbes R; Herbert K; Holland S; Jones KJ; Menezes MP; Morrison M; Munro K; Villano D; Webster R; Woodcock IR; Yiu EM; Sampaio H; Ryan MM
    J Neurol Neurosurg Psychiatry; 2018 Sep; 89(9):937-942. PubMed ID: 29549190
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nutritional Therapy in Children With Spinal Muscular Atrophy in the Era of Nusinersen.
    Yerushalmy-Feler A; Levy D; Sagi L; Fattal-Valevski A; Shiff YE; Brener A; Cohen S
    J Pediatr Gastroenterol Nutr; 2021 Jun; 72(6):e154-e160. PubMed ID: 33492038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.